Remove 2023 Remove Compliance Remove Regulatory Compliance Remove US Department of Health and Human Services
article thumbnail

December 2023 Regulatory Compliance Updates

Verisys

– The best resource for monthly healthcare regulatory compliance updates. US S3193 DEA: The DEA and Department of Health and Human Services (HHS) has announced the extension of current telemedicine flexibilities through December 31, 2024. 01ER ): Effective as a permanent rule on 11/13/2023.

article thumbnail

Show the benefits of investing in your healthcare regulatory compliance program

YouCompli

How to use the SBAR Framework. The same tool nurses use to communicate about health emergencies – can help you secure investment in your compliance department. . Over the past few years, I’ve helped many of our clients demonstrate the value of investing in compliance with an?SBAR. Explain your assessment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Strengthening Cybersecurity Preparedness for Small Organizations: Lessons from the Change Healthcare Ransomware Attack

HIT Consultant

The US health system is in a desperate cybersecurity state of affairs. Although the attack vector in the Change Healthcare breach has not been identified as of this writing, the same group was responsible for the massive MGM Resorts hack in September 2023 which started on LinkedIn with a social engineering-driven exploit.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – July/August

SQA

SQA Regulatory Surveillance Summary for July and August 2022. Health Canada. Health Canada is warning consumers about counterfeit BTNX Rapid Response COVID-19 antigen rapid test kits (25-pack boxes) found in Ontario. products in color and typeface and uses the BTNX Inc. and one distributor, Healthful Plus.

article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

In 2023 there seemed to be an unusually large number of other decisions that are likely to have a substantial impact on what we or our clients do, but involve either different products, non-product claims, or both. In 2023, these include United States ex rel. Executive Health Resources, Inc. , Another year bites the dust.

FDA 105